[Special Stock] DXVX Hits Upper Limit on News of Accelerated Obesity Treatment Development↑
Biohealthcare specialist company DXVX has hit the upper price limit (the highest daily price limit).
As of 2:42 PM on the 18th, DXVX is trading at 2,195 KRW, up 506 KRW (29.96%) from the previous trading day.
This rise appears to be driven by news accelerating the development of an oral obesity treatment.
Hot Picks Today
"Over 20 Times More Than Overseas": 104.5 Milli...
- Trump Says "In the End, We Will Make a Great Agreement" Ahead of Second Talks
- "Only the Top 1% Winning Big in Stocks Smile... '300 Million Won Splurges' or '1...
- "If an Accident Happens, Teachers Go to Jail"... The Real Reason Behind Fewer Sc...
- "Please Launch It in Korea!" After All the Hype... This Coffee Finally Arrives i...
On the same day, DXVX announced that based on previous research results confirming superiority over control substances in late-stage clinical trials, it is currently optimizing its oral GLP (glucagon-like peptide)-1 obesity drug candidate.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
